绝经后乳腺癌患者延长辅助内分泌治疗10年或更短疗程:系统评价与网络Meta分析
该系统评价与网络Meta分析检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials截至2023年4月30日发表的随机试验,评估绝经后切除乳腺癌患者延长内分泌治疗的最佳疗程。总体人群中延长5年对比2-3年和3-4年未显著改善无病生存期(HR=0.97,95%CI 0.88-1.08;HR=0.87,95%CI 0.72-1.06),总生存期不受延长内分泌治疗影响;作者认为初始5年治疗后延长2-3年芳香化酶抑制剂(AI)可考虑为获得无病生存期获益的合适方案。
要点
- 总体人群中延长5年对比2-3年无病生存期无显著差异(HR=0.97,95%CI 0.88-1.08)。
- 总体人群中延长5年对比3-4年无病生存期无显著差异(HR=0.87,95%CI 0.72-1.06)。
- 总生存期不受延长内分泌治疗影响;作者认为淋巴结阳性且初始他莫昔芬者10年疗程更具优势。
核心结论
- 作者认为初始5年治疗后延长2-3年芳香化酶抑制剂(AI)可考虑为获得无病生存期获益的合适方案。
- 作者观察认为淋巴结阳性乳腺癌患者10年疗程较更短疗程优势更大,尤其初始接受他莫昔芬者,并建议较长疗程在这些病例中为潜在标准治疗。
研究设计与样本
- 系统评价与网络Meta分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials截至2023年4月30日发表的延长内分泌治疗随机试验。
- 主要结局为无病生存期(DFS),次要终点为总生存期(OS);在贝叶斯框架下使用GeMTC包进行网络Meta分析,采用累积排名曲线下面积(SUCRA)p值确定相对排名,并进行网络Meta回归分析基线疾病特征和初始治疗的影响。
主要发现
- 总体人群中延长5年对比2-3年无病生存期无显著差异(HR=0.97,95%CI 0.88-1.08)。
- 总体人群中延长5年对比3-4年无病生存期无显著差异(HR=0.87,95%CI 0.72-1.06)。
- 该效应独立于辅助化疗和淋巴结状态;但延长5年AI在淋巴结阳性乳腺癌和初始接受他莫昔芬而非AI者中效果显著更好。
- 总生存期不受延长内分泌治疗影响。
临床怎么用
- 作者认为初始5年治疗后延长2-3年AI可考虑为获得无病生存期获益的合适方案。
- 作者建议淋巴结阳性乳腺癌患者、尤其初始接受他莫昔芬者,较长疗程(10年)为潜在标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adjuvant hormonal therapy, with or without prior chemotherapy, has been widely recognised as the preferred treatment strategy for resected breast cancer (BC) for a minimum duration of 5 years. If the effectiveness of therapy beyond a 5-year period has been established, there is still ongoing debate regarding the optimal duration for this prolonged period. A network meta-analysis (NMA) was conducted to ascertain the optimal duration of extended therapy for resected BC in postmenopausal women. MATERIAL AND METHODS: A comprehensive search was conducted on online databases, including MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, to identify all randomised trials on extended duration of endocrine therapy. The search was limited to trials that had been published before 30th April 2023. The study focused on evaluating disease-free survival (DFS) as the primary outcome, with overall survival (OS) as the secondary endpoint. Under the Bayesian framework, NMA was performed using the GeMTC package. The relative rankings of the treatments were determined by utilising surface under the cumulative ranking curve (SUCRA) p scores. A network meta-regression analysis was employed to ascertain the impact of the baseline characteristics of the disease and the initial treatments administered. RESULTS: In the overall population, increasing the duration by 5 years did not result in a significantly better DFS compared to durations of 2-3 and 3-4 more years (hazard ratio [HR] = 0.97, 95% confidence interval [CI] [0.88-1.08] and HR = 0.87, 95% CI [0.72-1.06]). This effect was independent of adjuvant chemotherapy and nodal status. However, the effect of 5 more years of AI was significantly better in node-positive BC and in those who received some years of tamoxifen instead of aromatase inhibitors (AIs) as initial adjuvant therapy. OS was not affected by the administration of extended endocrine therapy. CONCLUSIONS: We conclude that an extended course of AI lasting 2-3 years, following an initial 5-year treatment, may be considered an appropriate regimen for achieving DFS benefits. In node-positive BC cases, it has been observed that a duration of 10 years provides a greater advantage compared to shorter durations, especially when tamoxifen is administered initially. Therefore, it is suggested that a longer duration is a potential standard of care in these cases.
引用
- Petrelli F, Cavallone M, Dottorini L, et al. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis. Eur J Cancer. 2023. PMID: 37769477. doi:10.1016/j.ejca.2023.113322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。